Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 19/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 1/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cdp840 SCHEMBL29412448 | 1.00 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C | |
| Cdp840 SCHEMBL84490 | 1.00 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C | |
| Cdp840 SCHEMBL29351573 | 1.00 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C | |
| Cdp840 SCHEMBL153739 | 1.00 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C | |
| Cdp840 SCHEMBL15264054 | 0.99 | PDE4D (1.00) | PDE4APDE4DPDE4BPDE4C | |
| Cdp840 SCHEMBL16654879 | 0.99 | PDE4D (1.00) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL6251077 | 0.96 | PDE4A (0.92) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL1387380 | 0.95 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL1387378 | 0.95 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL1387472 | 0.95 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-H09510691-A | — | — | 1997-10-28 | — | — | JP | claimed |
| EP-0736010-A1 | AN ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF CHIRAL TRIARYL DERIVATIVES AND CHIRAL INTERMEDIATES FOR USE THEREIN | CELLTECH THERAPEUTICS LIMITED (GB) | 1996-10-09 | — | — | EP | claimed |
| WO-1995017386-A1 | AN ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF CHIRAL TRIARYL DERIVATIVES AND CHIRAL INTERMEDIATES FOR USE THEREIN | CELLTECH THERAPEUTICS LIMITED (GB) | 1995-06-29 | — | — | WO | claimed |
| EP-2193808-A1 | Synergistic combination | Nycomed GmbH (DE) | 2010-06-09 | — | — | EP | disclosed |
| US-20080085858-A1 | Pharmaceutical Composition | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-20080085858-A1 | Pharmaceutical Composition | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070287689-A1 | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
| US-20070287689-A1 | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
| EP-1813284-A1 | PHARMACEUTICAL COMPOSITION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1229034-B1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | PFIZER PROD INC (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004067006-A1 | COMBINATION OF A PDE IV INHIBITOR AND A TNF-ALPHA ANTAGONIST | PHARMACIA CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
| US-5608070-A | ENZYME INHIBITOR; ANTIINFLAMMATORY, BRONCHODILATOR AGENTS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-03-04 | — | — | US | disclosed |
| EP-0736010-A1 | AN ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF CHIRAL TRIARYL DERIVATIVES AND CHIRAL INTERMEDIATES FOR USE THEREIN | CELLTECH THERAPEUTICS LIMITED (GB) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995017386-A1 | AN ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF CHIRAL TRIARYL DERIVATIVES AND CHIRAL INTERMEDIATES FOR USE THEREIN | CELLTECH THERAPEUTICS LIMITED (GB) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | PDE4A 1/4885PDE4D 3/4885PDE4B 2/4885 |
| US-20080085858-A1 | Pharmaceutical Composition | PDE3B, PDE3A, PDE5A | PDE4A 4/4885PDE4D 10/4885PDE4B 5/4885 |
| US-20070287689-A1 | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | PDE4A, PDE3B, PDE2A | PDE4A 1/4885PDE4D 11/4885PDE4B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.